In8bio Inc (INAB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, In8bio Inc (INAB) has a cash flow conversion efficiency ratio of -0.204x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.75 Million) by net assets ($18.36 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see INAB stock market capitalisation for the company's overall valuation and market capitalisation.
In8bio Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how In8bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
In8bio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of In8bio Inc ranked by their cash flow conversion efficiency. See In8bio Inc (INAB) cash flow to debt to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Fibon Bhd
KLSE:0149
|
0.029x |
|
Impact Minerals Ltd
AU:IPT
|
-0.082x |
|
Aksara Global Development Tbk PT
JK:GAMA
|
-0.007x |
|
High Arctic Energy Services Inc.
TO:HWO
|
0.005x |
|
CADOGAN ENERGY SOLUTIONS
F:CPD
|
N/A |
|
Alfa Energi Investama Tbk PT
JK:FIRE
|
0.043x |
|
Great Divide Mining Ltd
AU:GDM
|
-0.092x |
|
Bawat Water Technologies AB
ST:BAWAT
|
-3.748x |
Annual Cash Flow Conversion Efficiency for In8bio Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of In8bio Inc from 2018 to 2025. View INAB stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $27.56 Million | $-12.71 Million | -0.461x | +72.34% |
| 2024-12-31 | $14.48 Million | $-24.15 Million | -1.668x | -78.21% |
| 2023-12-31 | $24.94 Million | $-23.34 Million | -0.936x | +11.79% |
| 2022-12-31 | $22.73 Million | $-24.12 Million | -1.061x | -199.92% |
| 2021-12-31 | $38.18 Million | $-13.51 Million | -0.354x | +9.13% |
| 2020-12-31 | $18.32 Million | $-7.13 Million | -0.389x | -102.81% |
| 2019-12-31 | $-346.00K | $-4.80 Million | 13.876x | +2428.66% |
| 2018-12-31 | $4.65 Million | $-2.77 Million | -0.596x | -- |
About In8bio Inc
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell… Read more